Merck, a science and technology firm, announced an additional investment of €40 million to build a manufacturing and distribution platform in Asia over two years. This follows its 2016 announcement of €80 million life science investment in China.
“In biopharmaceutical research, time is of the essence,” said Udit Batra, member, executive board, Merck and CEO, life science. “Our investments in the important Asian markets of South Korea, India and China ensure our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere.” The investments include setting up a manufacturing and distribution centre in Mumbai.
